Reconsidering the Role of Isoniazid in Drug-Resistant Tuberculosis

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2024 May 1

PMID 38691825

Authors

Geraint R Davies

Affiliations

Soon will be listed here.

References

Dooley K, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz S . Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial. Am J Respir Crit Care Med. 2020; 201(11):1416-1424. PMC: 7258626. DOI: 10.1164/rccm.201910-1960OC. View

Ahmad N, Ahuja S, Akkerman O, Alffenaar J, Anderson L, Baghaei P . Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018; 392(10150):821-834. PMC: 6463280. DOI: 10.1016/S0140-6736(18)31644-1. View

Katiyar S, Bihari S, Prakash S, Mamtani M, Kulkarni H . A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008; 12(2):139-45. View

Donald P, Sirgel F, Botha F, Seifart H, Parkin D, Vandenplas M . The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med. 1997; 156(3 Pt 1):895-900. DOI: 10.1164/ajrccm.156.3.9609132. View

Harausz E, Garcia-Prats A, Law S, Schaaf H, Kredo T, Seddon J . Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018; 15(7):e1002591. PMC: 6040687. DOI: 10.1371/journal.pmed.1002591. View

Donald P, Sirgel F, Venter A, Parkin D, Seifart H, van de Wal B . The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis. 2004; 39(10):1425-30. DOI: 10.1086/424999. View

Goodall R, Meredith S, Nunn A, Bayissa A, Bhatnagar A, Bronson G . Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022; 400(10366):1858-1868. PMC: 7614824. DOI: 10.1016/S0140-6736(22)02078-5. View

Van Deun A, Salim M, Das A, Bastian I, Portaels F . Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004; 8(5):560-7. View

Richardson M, Kirkham J, Dwan K, Sloan D, Davies G, Jorgensen A . variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019; 23(3):293-305. PMC: 6421944. DOI: 10.5588/ijtld.18.0324. View

10.

Nunn A, Phillips P, Meredith S, Chiang C, Conradie F, Dalai D . A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019; 380(13):1201-1213. DOI: 10.1056/NEJMoa1811867. View

11.

. Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach. Nat Commun. 2024; 15(1):488. PMC: 10786857. DOI: 10.1038/s41467-023-44325-5. View

12.

Gausi K, Ignatius E, de Jager V, Upton C, Kim S, McKhann A . High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. Am J Respir Crit Care Med. 2024; 210(3):343-351. PMC: 11348975. DOI: 10.1164/rccm.202311-2004OC. View

13.

Ahuja S, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona J . Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8):e1001300. PMC: 3429397. DOI: 10.1371/journal.pmed.1001300. View